HALEOSLABS vs JUBLPHARMA: Stock Comparison
JUBILANT PHARMOVA is the larger company by market capitalisation. HALEOS LABS shows a lower P/E, a higher ROE and a higher ROCE, while JUBILANT PHARMOVA shows a higher dividend yield, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
HALEOSLABS leads 6; JUBLPHARMA leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | HALEOSLABS | JUBLPHARMA |
|---|---|---|
| Sector | — | Healthcare |
| Industry | — | Pharmaceuticals |
Price
| Metric | HALEOSLABS | JUBLPHARMA |
|---|---|---|
| Live Price | ₹1,611.3 | ₹932.2 |
| Day Change | 1.74% | 0.3% |
| Volume | 895 | 1.08 L |
| 52-Week High | ₹1,774 | ₹1,183 |
| 52-Week Low | ₹1,181 | ₹786.05 |
| Distance from 52W High | -9.17% | -21.2% |
Valuation
| Metric | HALEOSLABS | JUBLPHARMA |
|---|---|---|
| Market Cap | ₹490 Cr | ₹14,757 Cr |
| P/E Ratio | 29.35x | 41.9x |
| P/B Ratio | 2.17x | 2.08x |
| EPS | ₹8.75 | ₹3.55 |
| Book Value | ₹759.29 | ₹445.48 |
| Dividend Yield | 0.09% | 0.54% |
Growth
| Metric | HALEOSLABS | JUBLPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 18.7% |
| EPS Growth (TTM YoY) | 0% | -22.4% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | HALEOSLABS | JUBLPHARMA |
|---|---|---|
| ROE | 7.75% | 5.6% |
| ROCE | 6.63% | 5.91% |
| Net Margin | 5.33% | 5.28% |
| Operating Margin | 9.48% | 9.98% |
| Debt to Equity | 0.47x | 0.45x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | HALEOSLABS | JUBLPHARMA |
|---|---|---|
| Promoter Holding | 72.11% | 44.39% |
| FII Holding | 0% | 15.87%▼ 0.03 pp |
| DII Holding | 0.31% | 12.4%▲ 0.78 pp |
| Public Holding | 27.58% | 23.5%▼ 0.74 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: HALEOS LABS and JUBILANT PHARMOVA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.